ERA4TB project
The ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative dedicated to accelerating the development of new TB treatment regimens, co-funded by the European programme H2020.
The ERA4TB consortium consists of 31 partners from the European Union and the United States, including major global players in the fight against tuberculosis infection, pharmaceutical companies and academia.
ERA4TB started in 2020 and will run for six years, at the end of which the consortium expects to have two or more new, safe, effective and potentially treatment-shortening combination regimens ready for Phase II clinical evaluation.
For more information: https://era4tb.org/
The Antimicrobials group of the University of Zaragoza is leading a work package dedicated to the in vitro characterisation of the new drug candidates against tuberculosis and its resistant strains. As a partner of the ERA4TB consortium, the University of Zaragoza implements the methodology, based on hollow fibre bioreactors, to study the efficacy of potential drug combinations.
Partners of the Work Package 2:
